PANGAEA ONCOLOGY

Trading sesion


07/04/2020 Close

1.7000

Last price


28.71 mill. €

Capitalisation

0.00

Dif.(%)


-

% Year

Last Trade

Date

07/04/2020

Hour

Close

Last

1.7000

Ref.

1.7000

Dif.(%)

0.00

Volume (Shares)

-

Turnover (€x1000)

-

X
07/04/2020 16:00:24
BidAsk
OrdersVolumePricePriceVolumeOrders
- - - 1.620016,0122

Security

Security name

PANGAEA ONCOLOGY

Ticker

PANG

ISIN

ES0105221008

NIF

A-64353584

Shares Admitted

16.886.546

Nominal

0,02 Euros

Capital Admitted

337.730,92 Euros

Trading

Fixing

Liquidity Provider

BANKINTER, S.A.

Registered Advisor

DCM ASESORES Dirección y Consultoría de Mercados, S.L.

Auditor

DELOITTE, S.L

Address

CL/ COSO 55, 50001 ZARAGOZA

Contact

investors@panoncology.com

Historical Summary

 20162017201820192020 until 7/04

Capital Admitted (thousands of euros)

212212262338338

Shares (x 1,000)

10,61010,61013,11016,88716,887

Period Close Price (euros)

3.00002.34002.22001.70001.7000

Period Last Price (euros)

3.00002.34002.22001.7000-  

Period High Price (euros)

3.00003.50002.46002.2000-  

Period Low Price (euros)

2.83002.31002.02001.7000-  

Capitalisation (thousands of euros)

31,83124,82829,10528,70728,707

Volume (thousands of shares)

3535151551,510184

Turnover (thousands of euros)

9561,5323552,227250

Company Profile

Founded in Barcelona in 2006, Pangaea Oncology is a medical services company focused on precision oncology, personalized medicine based on genetic analyses to improve survival and quality of life for cancer patients.

The company has two main areas of activity: (i) its clinical care division, the Dr. Rosell Oncology Institute (IOR). Based on the concept of personalized medicine, IOR delivers medical oncology services and related activities at four of the largest hospitals of the Quirónsalud Group in Catalonia; (ii) its Diagnostic and R & D services division, providing diagnostic and in-vitro services to IOR patients and Pangaea's portfolio of pharmaceutical clients, including over 15 multinationals. Pangaea is highly invested in technology, focusing on the development of innovative, proprietary diagnostic techniques (its main commercialized asset is Liquid Biopsy), and development of targeted drugs - to early clinical trial stages - through a strategic agreement with Cancer Research Technology, UK.
 
The synergy between these areas forms the foundation of Pangaea's future growth strategy. 

Relevant Facts and Notices

Significant participations

Photo Gallery

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.